News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ExonHit Therapeutics Inc. Announces Successful Completion of the Second Phase of EHT Dx14 Clinical Validation



7/19/2011 11:12:45 AM

PARIS--(BUSINESS WIRE)--Regulatory News: Following the first data in benign and malignant fine-needle aspiration (FNA) samples communicated on March 29, Exonhit (Paris:ALEHT) today announced successful completion of the second phase of the validation study of EHT Dx14, a new transcriptomic signature allowing to differentiate, at molecular level, benign breast tumors from malignant ones.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES